99 episodios
SPECIAL AHA RECAP focusing on seven studies: ZEUS & Ziltivekima; HORIZON & Pelacarsen; OPTIMAL-STROKE & BP Control; STREAM & Statin Therapy; OPTIMA-DIABETES & BP Control Through Yoga, OptimPacing & Left Bundle-Branch Pacing; COAST-AF & Ablation
12/11/2026 | 11 minIn this special edition of the View, Dr. Eagle looks at seven studies presented at the recent American Heart Association Conference that could have immediate effects on your practice. First, he discusses ZEUS: Interleukin-6 Inhibition With Ziltivekimab For High-Risk Patients With ASCVD, CKD and Systemic Inflammation, followed by Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a). Next, Dr. Eagle covered the OPTIMAL-STROKE trial that investigated whether intensive BP control targeting a systolic BP of 120 mm Hg or less in patients with elevated BP and previous ischemic stroke or TIA reduced the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for unstable angina or heart failure, then discussed STREAM, a trial that added new insights into statin therapy treatment. Additionally, Dr. Eagle summarized the OPTIMAL-DIABETES trial that addressed intensive blood pressure (BP) lowering through yoga-based cardiac rehab. Finally, Dr. Eagle discussed the international, multicenter OptimPacing trial that investigated if left bundle-branch pacing was superior to right ventricular pacing in reducing the risk of death from any cause, heart failure (HF) hospitalization, or pacing-induced cardiomyopathy, and concluded with a look at COAST-AF, that shed light on ablation-related procedures or medical treatment of patients after atrial fibrillation (AFib) ablation.
Get ACC's full coverage of the AHA conference here.
Subscribe to Eagle's Eye ViewSPECIAL TCT RECAP focusing on four studies: PROGRESS on TAVR & AS; SIMPLAFFY on NOACS & DAPT; SPYRAL AFFIRM on RDN & BP; IRIS MAIN on PCI & CABG
05/11/2026 | 10 minIn this special edition of the View, Dr. Eagle looks at four studies presented at the recent TCT Conference that could have immediate effects on your practice. First, he discusses PROGRESS, that investigated how TAVR may be superior to clinical surveillance in patients with moderate aortic stenosis (AS) with at-risk features. He then examined SIMPLAAFY, that explored how the use of reduced-dose non-vitamin K oral anticoagulants (NOACs) was noninferior to dual antiplatelet therapy (DAPT) for a composite of adverse clinical outcomes through six months following left atrial appendage closure (LAAC). He then takes a look at SPYRAL AFFIRM, on the effectiveness of radiofrequency RDN on blood pressure (BP) at six months. Finally, Dr. Eagle offers a summary of a non-randomized analysis of the IRIS-MAIN registry that indicated no statistically significant difference in long-term all-cause mortality among Asian patients with unprotected left main coronary artery disease (CAD) who underwent PCI or CABG. Get ACC's full coverage of the TCT conference here.
Subscribe to Eagle's Eye ViewUnderdiagnosis of AFib in Black Adults; Echocardiographic Evaluation; CAC Scores in Young Adults; Add-On Treatments For Resistant Hypertension
04/11/2026 | 8 minIn this week's View, Dr. Eagle looks at how black adults in disadvantaged neighborhoods are less likely to be diagnosed with atrial fibrillation (AFib). He then examines the parameters used to detect mitral regurgitation and how they might be improved. He follows that with a look at how high coronary artery calcium scores (CAC) in young adults can signal higher 30-year mortality. Finally, Dr. Eagle offers a comparison of add-on treatments for resistant or uncontrolled hypertension (HTN).
Subscribe to Eagle's Eye ViewFirefighters & Cardiac Death; HFimpEF & Sex Differences; DAPT, DOAC, and LAAO; Non-lnfarct-Related IRA & CAD
28/10/2026 | 9 minIn this week's View, Dr. Eagle looks at a brief report on how cardiac death remains a substantial contributor to on-duty mortality of U.S. firefighters, and how drivers of this trend may not be well identified by the current screening approaches. He then examines a recent article in JACC Heart Failure on how heart failure with improved ejection fraction (HFimpEF) was associated with better outcomes than persistent heart failure with reduced ejection fraction (HFrEF) in both women and men. He follows that with a look at a metanalysis that compared dual antiplatelet therapy (DAPT) and direct oral anticoagulant (DOAC) monotherapy and their effects on device-related thrombosis (DRT) and major bleeding after left atrial appendage occlusion (LAAO). Finally, Dr. Eagle offers a summary of an analysis a recent study the reported modest increase in noninfarct-related artery (non-IRA) revascularization in patients with STEMI and multivessel coronary artery disease (CAD), with some caveats.
Subscribe to Eagle's Eye ViewThe new ACC Scientific Statement on Exercise Prescription for CV Health, Multimodality Cardiac Imagine, Risk Stratification & CMR, Preventive PCI and CV Risk
21/10/2026 | 11 minIn this week's View, Dr. Eagle looks at the new ACC Scientific Statement on Exercise Prescriptions for Cardiovascular Health in Adults. He then examines a recent State-of-the-Art Review on the evolving role of multimodality cardiovascular imaging in the diagnosis and management of cardiac sarcoidosis (CS). He follows that with a look at a risk stratification model based on cardiac magnetic resonance (CMR) results. Finally, Dr. Eagle offers a summary of an analysis of the PREVENT trial on how preventive PCI lowers CV risk in patients with lipid-rich plaques.
Subscribe to Eagle's Eye View
Escucha Eagle's Eye View: Your Weekly CV Update From ACC.org, Ojalá lo hubiera sabido antes y muchos más podcasts de todo el mundo con la aplicación de radio.es

Descarga la app gratuita: radio.es
- Añadir radios y podcasts a favoritos
- Transmisión por Wi-Fi y Bluetooth
- Carplay & Android Auto compatible
- Muchas otras funciones de la app








































